Skip to content
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe
14Dec2025
  • Home
  • About
  • News
  • Subscribe
14Dec2025
Cost Curve NewsCost Curve News
Cost Curve News

J&J Puts Its 340B Rebate Efforts on Ice, But We’re Not Remotely Done Here

Apologies for the unexpected absence yesterday. It was the first official collegiate game for my social media manager, so my attention was elsewhere. She had quite the debut, including the
1 year ago
Keep Reading
Cost Curve News

The Newest 340B Tempest Raises Four Questions that Should Be Asked (But Aren’t)

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
1 year ago
Keep Reading
Cost Curve News

Celebrating a New Schizophrenia Drug … and Hoping The Value It Delivers Is Recognized

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
1 year ago
Keep Reading
Cost Curve News

The Power — and Limits — of Digital-Age Advocacy

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
1 year ago
Keep Reading
Cost Curve News

Bernie Suggests that PBMs Wouldn’t Penalize Novo for Price Cuts. The Reality Is More Complicated

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
1 year ago
Keep Reading
Cost Curve News

Sanders/Novo Faceoff Resurrects a Strawman: The Idea that Price and R&D Spend Are Connected

I have some thoughts on the obesity hearing today, but I have one other request: can we try to talk about the event without using the verb “to grill”? Not
1 year ago
Keep Reading
Cost Curve News

The FTC vs PBM Slugfest Continues as the Government Sues the Middlemen Over Insulin Rebates

There is a lot to talk about this morning, but I don’t want to lose track of the fact that my social media manager scored the game-winning goal in her
1 year ago
Keep Reading
Cost Curve News

JNJ’s Industry-Defining Price Transparency Report Is Out

And here, I thought I’d get the last Curve of the week out in the morning. Thanks for your patience.  And thanks to Jennifer Kim, Josh Schimmer, and my fellow
1 year ago
Keep Reading
Cost Curve News

Bernie Sanders: Still Not Being Constructive on Obesity Pricing

This should be the last day of late Curves for the week. Back at you in the morning tomorrow. Probably off Friday for Terrier game day. My gut on the
1 year ago
Keep Reading
Cost Curve News

A KFF IRA Survey Shows Just How Little the Average Americans Are Tracking on Health Policy

We’re into the heavy part of the drug-wonk season, so today’s newsletter packs in -- frankly -- a bit more than I would ordinarily like to throw at you (especially
1 year ago
Keep Reading
282930

Latest Posts

A New Tracker for Watching Meds That Might See Prices Slashed

December 10, 2025

Why IRA ‘Negotiations’ and MFN Dealmaking Led to Such Different Prices for Ozempic and Wegovy

December 9, 2025

Reimbursement for Hep B Shots Should Remain Stable Even as CDC Panel Undermines the Vaccine

December 8, 2025

A New Health Affairs Forefront Piece Seeks to Reset the ‘Pharm-to-Table’ Conversation

December 5, 2025

Companies and Nations Respond to the U.S.-U.K. Agreement to Eliminate Tariffs, Boost Drug Prices

December 4, 2025

Popular

A New Tracker for Watching Meds That Might See Prices Slashed

Why IRA ‘Negotiations’ and MFN Dealmaking Led to Such Different Prices for Ozempic and Wegovy

Reimbursement for Hep B Shots Should Remain Stable Even as CDC Panel Undermines the Vaccine

A New Health Affairs Forefront Piece Seeks to Reset the ‘Pharm-to-Table’ Conversation

Companies and Nations Respond to the U.S.-U.K. Agreement to Eliminate Tariffs, Boost Drug Prices

The Need-to-Know on a Slow News Day: More MFN Deals Are Coming, and Why Pharma Thinks the U.S./U.K. Trade Agreement Should Be a Model

Most Viewed
  • CMS Patient-Focused Listening Session Transcripts (2,942)
  • New JAMA Research Shows How Much — and How Rapidly — Part D Plans Have Shifted Drug Costs to Consumers (2,036)
  • Working Out the Strange Math and Weird Consequences of IRA Inflation Penalties (1,924)
  • Bernie Sanders Wants to Talk to CEOs About US vs ROW Pricing. Bring It On, I Say. (1,723)
  • More IRA Lawsuits Coming, PhRMA Chief Predicts (1,716)

Your trusted source for daily updates on drug pricing and policy. Stay informed and ahead of the curve with Cost Curve News.

Latest News

A New Tracker for Watching Meds That Might See Prices Slashed

December 10, 2025

Why IRA ‘Negotiations’ and MFN Dealmaking Led to Such Different Prices for Ozempic and Wegovy

December 9, 2025

Subcribe To Newsletter

Subscribe to our newsletter and stay informed about new posts and stay up-to-date on the latest news
Subscribe
© 2025 Cost Curve News | All Rights Reserved
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe